| Project/Area Number |
23591914
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
TOH Uhi 久留米大学, 医学部, 准教授 (60268901)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KOMATSU Nobukazu 久留米大学, 医学部, 講師 (50343687)
関 直子 久留米大学, 医学部, 講師 (40226634)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SEKI Naoko 久留米大学, 医学部, 講師 (40226634)
|
|---|
| Project Period (FY) |
2011-04-28 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 乳がん / がんﾍﾟﾌﾟﾁﾄﾞﾜｸﾁﾝ / ペプチドワクチン / がんペプチドワクチン / がん免疫療法 / 乳癌 / 癌免疫療法 / ペプチドワクチン療法 |
|---|
| Outline of Final Research Achievements |
Personalized peptide vaccination (PPV) therapy has been developed in Kurume University for various solid cancers, in which vaccines are selected from 31 different peptides before vaccination. In this study, we conducted a phase II trial for metastatic recurrent breast cancer (mrBC) patients to investigate the feasibility of PPV. 79 patients with mrBC who had failed standard chemo- and/or endocrine therapy were enrolled. Two to four HLA-matched peptides were selected and were subcutaneously administered. Cytotoxic T lymphocyte (CTL) and IgG responses were measured and immune boosting was observed irrespectively with mrBC subtypes. No severe adverse events were observed. Response was 3 CR and 6 PR. The median progression-free survival time and median overall survival time were 7.5 and 15.9 months. PPV could be feasible for mrBC patients and the combination of chemo- or endocrine therapy might be a novel therapeutic strategy that predominantly targets the tumor-associated antigens.
|
